AI-generated analysis. Always verify with the original filing.
Daré Bioscience, Inc. completed the second closing of its previously announced unregistered securities offering on March 6, 2026, as disclosed in this Form 8-K filing dated March 9, 2026. This event falls under Item 3.02, indicating an unregistered sale of equity securities that may impact the company's capitalization and shareholder base.
Event Type
Disclosure
Mandatory
Variant
8-K
Unregistered Sales of Equity Securities. On March 6, 2026, Daré Bioscience, Inc. (“Daré” “we,” “us,” or “our”) completed the second closing of its previously an